Cephalon Articles
Fentora performs well in Ph III pain trial
7 May 2007
Stock Commentary - New York week to April 2
9 April 2007
Cephalon's Nuvigil gets tentative OK from FDA
9 April 2007
Cephalon files fentanyl buccal tablet with EMEA
2 April 2007
Stock Commentary - New York week to March 5, 2007
12 March 2007
Waxman investigates marketing practices
12 March 2007
Barr posts $391M net loss in 4th qtr 2006
12 March 2007
Stock Commentary - New York week to Feb 19, 2007
26 February 2007
Cephalon promotes Mike Barr
19 February 2007
Cephalon sees 4th-qtr losses hit $4.9M
19 February 2007
Alkermes reports $3M 4th-qtr 2006 net income
19 February 2007
Cephalon welcomes NCI Trisenox trial data
5 February 2007
Italy's MoH requests Insmed's Iplex for ALS treatment
15 January 2007
Beijing Med-Pharma in deal with Cephalon
18 December 2006
Stock Commentary - New York week to Dec 11, 2006
18 December 2006
Cephalon promotes Raj Khankari at CIMA Labs unit
11 December 2006
Cephalon updates on final Nuvigil labeling
11 December 2006
Lestaurtinib gets EU OD designation for AML
27 November 2006
Cephalon's 3rd-qtr 2006 sales increases 56%
13 November 2006
Fentora Ph III pain study produces positive data
23 October 2006
Promotions at Cephalon Europe
9 October 2006
US FDA approves Cephalon's Fentora
2 October 2006
Biotech stocks in holding pattern for August, says Burrill report
18 September 2006
Cephalon promotes Lesley Russell
4 September 2006
Cephalon swings to profit in 2nd-qtr 2006
14 August 2006
Law firm Olswang expands bioscience capability
17 July 2006
Stock Commentary - New York week to July 3, 2006
10 July 2006
Fentora viewed as approvable by US FDA
10 July 2006
Japan stock market week to June 19, 2006
26 June 2006
Cephalon/Takeda to promote Provigil in US
19 June 2006
UK science chief advocates "smart drugs"
12 June 2006
Cephalon's Sparlon safe and effective for ADHD
29 May 2006
Pharmacopeia and Cephalon alliance
29 May 2006
FDA approves Vivitrol for alcohol dependency
24 April 2006
Japan stock market week to April 10, 2006
17 April 2006
Stock Commentary - New York week to March 27, 2006
3 April 2006
Stock Commentary - New York week to Mar 20, 2006
27 March 2006
Cephalon's full-year 2005 loss deepens 130%
27 February 2006
Pharma/biotech mergers and acquisitions during 2005
6 February 2006
SPECTRUM week to Jan 9
9 January 2006
Stock Commentary - New York week to Jan 9
9 January 2006
Cephalon's CEP-701 sees good Ph II data
9 January 2006
Vivitrol gains FDA approvable letter
9 January 2006
Cephalon and Teva settle Provigil patent dispute
19 December 2005
SPECTRUM week to Dec 12
19 December 2005
Cephalon's Sparlon improves ADHD symptoms in children
12 December 2005
Cephalon makes $360M cash offer for Zeneus
12 December 2005
Stock Commentary - New York week to Sept 5
12 September 2005
SPECTRUM week to Aug 15
12 September 2005
McNeil to co-promote modafinil for ADHD with Cephalon
5 September 2005
S-P to begin distribution of drug using CIMA's OraSolv
5 September 2005
Cephalon sees 19% sales jump in 2nd qtr
15 August 2005
Provagil "improves wakefulness"
15 August 2005
Stock Commentary - New York
11 July 2005
Cephalon signs Vivitrex deal with Alkermes
4 July 2005
Cephalon completes Salmedix buy
20 June 2005
Cephalon buys into cancer therapy sector
20 June 2005
Cephalon prices $800M offering
20 June 2005
Stock Commentary - New York
6 June 2005
Stock Commentary - New York
23 May 2005
Cephalon/Lundbeck terminate PD drug trial
23 May 2005
Cephalon to buy Salmedix for $160M
23 May 2005
Cephalon files NDA with FDA for Nuvigil
11 April 2005
Cephalon's sugar-free analgesic nears FDA OK
4 April 2005
Cephalon post record results for 2004
28 February 2005
Promotions at Cephalon Europe
21 February 2005
Positive Ph III data for Cephalon's Nuvigil
21 February 2005
Generic approvals for Mylan and Teva
21 February 2005
Highlights of pharmaceutical mergers and acquisitions in 2004
24 January 2005
Stock Commentary - New York
22 November 2004
Cephalon's 3rd-qtr loss grows on charges
15 November 2004
UK NICE OKs Novartis' Gleevec as first-line GIST management, also views epilepsy care
8 November 2004
Stock Commentary - New York
20 September 2004
Cephalon appoints Elizabeth Mutisya VP medical affairs and promotes Robert Hrubiec
20 September 2004
Cephalon subpoenaed by US Attorney's Office
20 September 2004
In August, biotech emerges from doldrums, but uncertainty persists: Burrill review
13 September 2004
Stock Commentary - New York
23 August 2004
Stock Commentary - New York
16 August 2004
US FTC clears way for Cephalon's acquisition of CIMA
16 August 2004
Cephalon and CIMA merger agreed by FTC in principle
12 July 2004
Shareholders approve Cephalon/CIMA merger
21 June 2004
Cephalon's 1st-qtr sales up 49% to $215M
10 May 2004
UK NICE guidance on insomnia drugs
10 May 2004
Provigil cleared for new use in UK
19 April 2004
UK NICE backs newer antiepileptics
29 March 2004
Cephalon's Provigil shows promise in schizophrenia
22 March 2004
Cephalon names Kenneth Fiorelli VP, global process development
16 February 2004
Cephalon files $1 bill shelf registration
16 February 2004
FDA OKs expanded use of Provigil
2 February 2004
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
